Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Cleared to Offer Cyto Array Services to New York State Residents

Premium

By Justin Petrone

CombiMatrix has received a clinical laboratory permit from the New York State Department of Health. The Irvine, Calif.-based molecular diagnostics firm can immediately begin receiving specimens from New York residents for its DNAarray postnatal developmental testing service, according to the firm's CEO.

Judd Jessup told BioArray News called the receipt of the permit an "important certification" that the firm can rely on when talking to potential clients." He added that the licensure gives CombiMatrix a "market advantage" over testing companies that lack one and therefore cannot service customers in New York.

While CombiMatrix's suite of array-based constitutional and oncology tests is offered via its US Clinical Laboratory Improvement Amendments-compliant lab, the firm has been unable to offer its services in states where more stringent standards for clinical testing supersede federally regulated CLIA standards without obtaining local certification.

The clearance comes roughly two years after New York informed CombiMatrix that it would require a state license to offer its array comparative genomic hybridization-based test. The firm had been offering the test to New Yorkers since it was launched in 2006.

Jessup said that CombiMatrix now hopes to recapture some of its customer base. "Since we were providing these tests to customers in the past, now that we are licensed we will be contacting them and seeking to regain their business," he said.

He added that the company will seek similar permits for its other tests both in the developmental and oncology segments of its business.

In addition to the New York permit, CombiMatrix has obtained clinical laboratory licenses "from all major states, including California, Florida, Pennsylvania, Maryland, and Rhode Island," in addition to its CLIA and College of American Pathologist accreditation.

According to its website, the firm's DNAarray Oligo 180K platform can be used to screen individuals for 260 developmental disorders caused by gains and losses of specific chromosomal regions, as well as more than 100 loci associated with autism spectrum disorders and 510 genes associated with congenital anomalies and developmental delays.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.